Coronavirus

Aaron Bell Excerpts

Wednesday 17th June 2020 Commons Chamber

[Matt Hancock]

The hon. Gentleman raises three points. First, we have put a huge amount of effort into ensuring that the local-to-national links are strong in test and trace. I pay tribute to Tom Riordan, the chief executive of Leeds City Council, who has come into the programme on secondment from Leeds in order to deliver those links. He has done an absolutely brilliant job, and I pay tribute to him. On the hon. Gentleman’s second point, we do not rule out mandatory contact tracing, but we want to get the system up and running, and it would be far better if it worked on a voluntary basis in the first instance. On his third point, we have put in place more support to ensure that people get the financial support they need to be able to do the right thing. The evidence is that the vast majority of people do, but of course we keep this under review.

[Aaron Bell (Newcastle-under-Lyme) (Con)]

I join my right hon. Friend in welcoming the tremendous news on treatment with dexamethasone. Following on from that, can he update the House first on what progress we are making towards a vaccine, and secondly on what progress we are making with our manufacturing capacity for a vaccine, so that when we get it we are able to roll it out at speed, including with Cobra Biologics in my constituency?

[Matt Hancock]

I am absolutely determined that should a vaccine come through, we are able to roll it out—in the first instance to those who are most vulnerable—across the UK, including to my hon. Friend’s constituents in Newcastle-under-Lyme. That is incredibly important. As I said in my statement, AstraZeneca has now signed the contract to manufacture the vaccine, even ahead of the successful conclusion of clinical trials, which shows confidence. The Imperial vaccine, which is not as far ahead as the Oxford vaccine, but is promising and based on a different vaccine technology, which is important—it is slightly different—has gone into human trials as well.